Frankenius Equity AB bought $250k of TLSI
owner at TriSalus Life Sciences, Inc.. 62,972 shares at an average of $3.97, traded Dec 17, 2024, filed Dec 19, 2024.
Score components
- +12Role10% owner
- +13Trade size$250k at market
- 0Relative to holdingsHoldings up 1.0%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-029904, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 17, 2024 | POpen-market purchase Common Stock | +62,972 | $3.97 | $250k | 6,230,748 | Dec 19, 2024 |
Related signals
Other insiders at TriSalus Life Sciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | TriSalus Life Sciences, Inc. | Bryan F. Cox Chief of Research | $1,299 296 shares | -0% | |
| 30Weak | TriSalus Life Sciences, Inc. | Richard Marshak Chief Commercial Officer | $1,427 325 shares | -0% | |
| 30Weak | TriSalus Life Sciences, Inc. | Jennifer Stevens Chief Regulatory Officer | $1,387 316 shares | -0% | |
| 30Weak | TriSalus Life Sciences, Inc. | Bryan F. Cox Chief of Research | $13k 3,184 shares | -2% | |
| 30Weak | TriSalus Life Sciences, Inc. | Jodi Devlin Chief of Clinical Operations | $13k 3,207 shares | -3% | |
| 30Weak | TriSalus Life Sciences, Inc. | Richard Marshak Chief Commercial Officer | $14k 3,457 shares | -3% | |
| 30Weak | TriSalus Life Sciences, Inc. | Jennifer Stevens Chief Regulatory Officer | $15k 3,530 shares | -3% | |
| 49Moderate | TriSalus Life Sciences, Inc. | Mary T Szela CEO and President | $79k 20,302 shares | -3% | |
| 52Moderate | TriSalus Life Sciences, Inc. | Gary B. Gordon director | $40k 9,756 shares | - | |
| 45Moderate | TriSalus Life Sciences, Inc. | David Patience Chief Financial Officer | $15k 3,657 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.